Abstract
New anti-infective strategies for treatment of tularemia
Highlights
This collection of 10 articles in Frontiers and Cellular Microbiology aims to present the current opportunities for development of innovative therapeutic strategies for tularemia, a zoonotic disease caused by Francisella tularensis
Two F. tularensis subspecies are responsible for tularemia in humans, subsp. holarctica in the northern hemisphere and subsp. tularensis in North America, which themselves are split into genotypes of variable virulence
There is no vaccine for tularemia, and few antibiotics are effective in treating tularemia patients, including the aminoglycosides, the fluoroquinolones and the tetracyclines
Summary
This collection of 10 articles in Frontiers and Cellular Microbiology aims to present the current opportunities for development of innovative therapeutic strategies for tularemia, a zoonotic disease caused by Francisella tularensis. Tularemia is a relevant model for development of modern anti-infective alternatives. Because tularemia is a rare disease, clinical trials in infected humans for comparing different therapeutic strategies are not feasible.
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call